ΕΠΙΗΜΗ ΕΦΗΜΕΡΙΔΑ ΣΗ ΚΤΠΡΙΑΚΗ ΔΗΜΟΚΡΑΣΙΑ

Σχετικά έγγραφα
ΚΑΤΑΛΟΓΟΣ ΑΠΑΓΟΡΕΥΜΕΝΩΝ ΟΥΣΙΩΝ ΚΑΙ ΜΕΘΟΔΩΝ ΓΙΑ ΤΟ 2013

ΚΑΤΑΛΟΓΟΣ ΑΠΑΓΟΡΕΥΜΕΝΩΝ ΟΥΣΙΩΝ ΚΑΙ ΜΕΘΟΔΩΝ ΓΙΑ ΤΟ 2012

ΚΑΤΑΛΟΓΟΣ ΑΠΑΓΟΡΕΥΜΕΝΩΝ ΟΥΣΙΩΝ ΚΑΙ ΜΕΘΟΔΩΝ ΓΙΑ ΤΟ 2011

ΚΑΤΑΛΟΓΟΣ ΑΠΑΓΟΡΕΥΜΕΝΩΝ ΟΥΣΙΩΝ ΚΑΙ ΜΕΘΟΔΩΝ ΓΙΑ ΤΟ 2014

ΚΑΤΑΛΟΓΟΣ ΑΠΑΓΟΡΕΥΜΕΝΩΝ ΟΥΣΙΩΝ ΚΑΙ ΜΕΘΟΔΩΝ ΓΙΑ ΤΟ 2010 ΔΙΕΘΝΕΙΣ ΠΡΟΔΙΑΓΡΑΦΕΣ

ΑΝΑΡΤΗΤΕΑ ΣΤΟ ΔΙΑΔΙΚΤΥΟ. ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ ΥΠΟΥΡΓΕΙΟ ΠΟΛΙΤΙΣΜΟΥ & ΤΟΥΡΙΣΜΟΥ Αθήνα, ΓΕΝΙΚΗ ΓΡΑΜΜΑΤΕΙΑ ΑΘΛΗΤΙΣΜΟΥ

ΘΕΜΑ : Καθορισμός απαγορευμένων ουσιών και μεθόδων ντόπινγκ, κατά την έννοια των άρθρων 128Β και 128Γ του ν. 2725/1999.

ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

ΘΕΜΑ : Καθορισμός απαγορευμένων ουσιών και μεθόδων ντόπινγκ, κατά την έννοια των άρθρων 128Β και 128Γ του ν. 2725/1999.

Απαγορευμένες Ουσίες και Μέθοδοι

PRAVILNIK O LISTI ZABRANJENIH DOPING SREDSTAVA

Case 1: Original version of a bill available in only one language.

З А К О Н О ПОТВРЂИВАЊУ МЕЂУНАРОДНЕ КОНВЕНЦИЈЕ ПРОТИВ ДОПИНГА У СПОРТУ

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΓΕΩΠΟΝΙΚΩΝ ΕΠΙΣΤΗΜΩΝ ΒΙΟΤΕΧΝΟΛΟΓΙΑΣ ΚΑΙ ΕΠΙΣΤΗΜΗΣ ΤΡΟΦΙΜΩΝ. Πτυχιακή εργασία

derivation of the Laplacian from rectangular to spherical coordinates

the total number of electrons passing through the lamp.

Mean bond enthalpy Standard enthalpy of formation Bond N H N N N N H O O O

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ

3.5.4 Ο αυξητικός παράγοντας BMP Ο αυξητικός παράγοντας FGF Αυξητικός παράγοντας PDGF (Platelet Derived Growth Factor)...

Math 6 SL Probability Distributions Practice Test Mark Scheme

Službeni glasnik BiH, broj 87/17

ΠΑΝΔΠΗΣΖΜΗΟ ΠΑΣΡΩΝ ΣΜΖΜΑ ΖΛΔΚΣΡΟΛΟΓΩΝ ΜΖΥΑΝΗΚΩΝ ΚΑΗ ΣΔΥΝΟΛΟΓΗΑ ΤΠΟΛΟΓΗΣΩΝ ΣΟΜΔΑ ΤΣΖΜΑΣΩΝ ΖΛΔΚΣΡΗΚΖ ΔΝΔΡΓΔΗΑ

Η ΕΠΙΔΡΑΣΗ ΤΗΣ ΑΙΘΑΝΟΛΗΣ,ΤΗΣ ΜΕΘΑΝΟΛΗΣ ΚΑΙ ΤΟΥ ΑΙΘΥΛΟΤΡΙΤΟΤΑΓΗ ΒΟΥΤΥΛΑΙΘΕΡΑ ΣΤΙΣ ΙΔΙΟΤΗΤΕΣ ΤΗΣ ΒΕΝΖΙΝΗΣ

encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ BIOCHEMICAL JOURNAL

Every set of first-order formulas is equivalent to an independent set

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΕΙΡΑΙΑ ΤΜΗΜΑ ΝΑΥΤΙΛΙΑΚΩΝ ΣΠΟΥΔΩΝ ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ ΣΤΗΝ ΝΑΥΤΙΛΙΑ

The Simply Typed Lambda Calculus

Επίδραση της Συμβολαιακής Γεωργίας στην Χρηματοοικονομική Διοίκηση των Επιχειρήσεων Τροφίμων. Ιωάννης Γκανάς

Η Α ΕΝΟΫΠΟΦΥΣΗ: OI ΓΟΝΑ ΟΤΡΟΠΙΝΕΣ (FSH, LH) ΚΑΙ Η ΠΡΟΛΑΚΤΙΝΗ (PRL)

In vitro και in vivo φαρμακοκινητική ανάλυση των παραγώγων ανθρακινόνης σε φυτικά σκευάσματα

Approximation of distance between locations on earth given by latitude and longitude

ΔΙΕΡΕΥΝΗΣΗ ΤΗΣ ΣΕΞΟΥΑΛΙΚΗΣ ΔΡΑΣΤΗΡΙΟΤΗΤΑΣ ΤΩΝ ΓΥΝΑΙΚΩΝ ΚΑΤΑ ΤΗ ΔΙΑΡΚΕΙΑ ΤΗΣ ΕΓΚΥΜΟΣΥΝΗΣ ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ

Strain gauge and rosettes

Α ιθ EL. 3. Κα ασ ασ ής: fischerwerke GmbH & Co. KG, Klaus-Fischer-Straße 1, Waldachtal, α ία. Tumlingen,

AME SAMPLE REPORT James R. Cole, Ph.D. Neuropsychology

Εργαστήριο Ανάπτυξης Εφαρμογών Βάσεων Δεδομένων. Εξάμηνο 7 ο

ΕΦΗΜΕΡΙ Α ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

ΕΘΝΙΚΟ ΜΕΤΣΟΒΙΟ ΠΟΛΥΤΕΧΝΕΙΟ ΣΧΟΛΗ ΠΟΛΙΤΙΚΩΝ ΜΗΧΑΝΙΚΩΝ. «Θεσμικό Πλαίσιο Φωτοβολταïκών Συστημάτων- Βέλτιστη Απόδοση Μέσω Τρόπων Στήριξης»

Assalamu `alaikum wr. wb.

Πολιτιστικό Προφίλ Δήμου Κορυδαλλού

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΓΕΩΠΟΝΙΚΩΝ ΕΠΙΣΤΗΜΩΝ ΚΑΙ ΔΙΑΧΕΙΡΙΣΗΣ ΠΕΡΙΒΑΛΛΟΝΤΟΣ. Πτυχιακή διατριβή

Main source: "Discrete-time systems and computer control" by Α. ΣΚΟΔΡΑΣ ΨΗΦΙΑΚΟΣ ΕΛΕΓΧΟΣ ΔΙΑΛΕΞΗ 4 ΔΙΑΦΑΝΕΙΑ 1

ΟΡΓΑΝΙΣΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗΣ ΙΔΙΟΚΤΗΣΙΑΣ

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ. Πτυχιακή εργασία Η ΚΑΤΑΘΛΙΨΗ ΣΕ ΕΦΗΒΟΥΣ ΜΕ ΣΑΚΧΑΡΩΔΗ ΔΙΑΒΗΤΗ ΤΥΠΟΥ 1

ΓΕΩΠΟΝΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΤΜΗΜΑ ΑΓΡΟΤΙΚΗΣ ΟΙΚΟΝΟΜΙΑΣ & ΑΝΑΠΤΥΞΗΣ

Πτυχιακή Εργασία Η ΠΟΙΟΤΗΤΑ ΖΩΗΣ ΤΩΝ ΑΣΘΕΝΩΝ ΜΕ ΣΤΗΘΑΓΧΗ

This is an electronic reprint of the original article. This reprint may differ from the original in pagination and typographic detail.

ΣΗΣΛΟ: Ζ ΥΡΖΖ ΒΗΟΛΟΓΗΚΧΝ ΠΡΟΗΟΝΣΧΝ ΣΟΝ ΑΓΡΟΣΟΤΡΗΜΟ

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ ΦΙΛΟΣΟΦΙΚΗ ΣΧΟΛΗ ΤΜΗΜΑ ΙΤΑΛΙΚΗΣ ΦΙΛΟΛΟΓΙΑΣ ΜΕΤΑΠΤΥΧΙΑΚΟΣ ΚΥΚΛΟΣ ΣΠΟΥΔΩΝ ΚΑΤΕΥΘΥΝΣΗ: ΛΟΓΟΤΕΧΝΙΑ-ΠΟΛΙΤΙΣΜΟΣ

Η ΠΡΟΣΩΠΙΚΗ ΟΡΙΟΘΕΤΗΣΗ ΤΟΥ ΧΩΡΟΥ Η ΠΕΡΙΠΤΩΣΗ ΤΩΝ CHAT ROOMS

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΝΟΣΗΛΕΥΤΙΚΗΣ ΠΤΥΧΙΑΚΗ ΕΡΓΑΣΙΑ ΕΠΗΡΕΑΖΕΙ ΤΗΝ ΠΡΟΛΗΨΗ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ

ΤΕΧΝΟΛΟΓΙΚΟ ΕΚΠΑΙ ΕΥΤΙΚΟ Ι ΡΥΜΑ ΚΡΗΤΗΣ ΣΧΟΛΗ ΙΟΙΚΗΣΗΣ ΚΑΙ ΟΙΚΟΝΟΜΙΑΣ ΤΜΗΜΑ ΙΟΙΚΗΣΗΣ ΕΠΙΧΕΙΡΗΣΕΩΝ ΠΤΥΧΙΑΚΗ ΕΡΓΑΣΙΑ

«ΑΓΡΟΤΟΥΡΙΣΜΟΣ ΚΑΙ ΤΟΠΙΚΗ ΑΝΑΠΤΥΞΗ: Ο ΡΟΛΟΣ ΤΩΝ ΝΕΩΝ ΤΕΧΝΟΛΟΓΙΩΝ ΣΤΗΝ ΠΡΟΩΘΗΣΗ ΤΩΝ ΓΥΝΑΙΚΕΙΩΝ ΣΥΝΕΤΑΙΡΙΣΜΩΝ»


6.1. Dirac Equation. Hamiltonian. Dirac Eq.

GREECE BULGARIA 6 th JOINT MONITORING

EE512: Error Control Coding

ΕΘΝΙΚΗ ΣΧΟΛΗ ΔΗΜΟΣΙΑΣ ΔΙΟΙΚΗΣΗΣ ΙΓ' ΕΚΠΑΙΔΕΥΤΙΚΗ ΣΕΙΡΑ

CORDIC Background (4A)

Molecular evolutionary dynamics of respiratory syncytial virus group A in

Phys460.nb Solution for the t-dependent Schrodinger s equation How did we find the solution? (not required)

CYPRUS UNIVERSITY OF TECHNOLOGY Faculty of Geotechnical Sciences and Environmental Management Department of Environmental Science and Technology

Ελληνικό ιαδραστικό Σχολείο. Ουρολογίας 18-21/4/2013. Πορταριά Πήλιο

Θωμάς ΣΑΛΟΝΙΚΙΟΣ 1, Χρήστος ΚΑΡΑΚΩΣΤΑΣ 2, Βασίλειος ΛΕΚΙΔΗΣ 2, Μίλτων ΔΗΜΟΣΘΕΝΟΥΣ 1, Τριαντάφυλλος ΜΑΚΑΡΙΟΣ 3,

ΑΚΑ ΗΜΙΑ ΕΜΠΟΡΙΚΟΥ ΝΑΥΤΙΚΟΥ ΜΑΚΕ ΟΝΙΑΣ ΣΧΟΛΗ ΜΗΧΑΝΙΚΩΝ ΠΤΥΧΙΑΚΗ ΕΡΓΑΣΙΑ

ΙΠΛΩΜΑΤΙΚΗ ΕΡΓΑΣΙΑ. ΘΕΜΑ: «ιερεύνηση της σχέσης µεταξύ φωνηµικής επίγνωσης και ορθογραφικής δεξιότητας σε παιδιά προσχολικής ηλικίας»

Congruence Classes of Invertible Matrices of Order 3 over F 2

Τ.Ε.Ι. ΔΥΤΙΚΗΣ ΜΑΚΕΔΟΝΙΑΣ ΠΑΡΑΡΤΗΜΑ ΚΑΣΤΟΡΙΑΣ ΤΜΗΜΑ ΔΗΜΟΣΙΩΝ ΣΧΕΣΕΩΝ & ΕΠΙΚΟΙΝΩΝΙΑΣ

PARTIAL NOTES for 6.1 Trigonometric Identities

ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΕΙΡΑΙΩΣ ΤΜΗΜΑ ΝΑΥΤΙΛΙΑΚΩΝ ΣΠΟΥΔΩΝ ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ ΣΤΗ ΝΑΥΤΙΛΙΑ

ΓΗΠΛΧΜΑΣΗΚΖ ΔΡΓΑΗΑ ΑΡΥΗΣΔΚΣΟΝΗΚΖ ΣΧΝ ΓΔΦΤΡΧΝ ΑΠΟ ΑΠΟΦΖ ΜΟΡΦΟΛΟΓΗΑ ΚΑΗ ΑΗΘΖΣΗΚΖ

Jesse Maassen and Mark Lundstrom Purdue University November 25, 2013

Συντακτικές λειτουργίες

Reminders: linear functions

ΙΑΤΡΟΦΙΚΗ ΦΡΟΝΤΙ Α ΓΙΑ ΤΑΞΙ ΙΩΤΕΣ ΣΥΝΤΟΜΗΣ ΚΑΙ ΜΑΚΡΑΣ ΙΑΡΚΕΙΑΣ

Section 8.3 Trigonometric Equations

Démographie spatiale/spatial Demography

ΤΕΙ ΚΑΒΑΛΑΣ ΣΧΟΛΗ ΤΕΧΝΟΛΟΓΙΚΩΝ ΕΦΑΡΜΟΓΩΝ ΤΜΗΜΑ ΗΛΕΚΤΡΟΛΟΓΙΑΣ ΠΤΥΧΙΑΚΗ ΕΡΓΑΣΙΑ

MSM Men who have Sex with Men HIV -

ΠΑΡΑΜΕΤΡΟΙ ΕΠΗΡΕΑΣΜΟΥ ΤΗΣ ΑΝΑΓΝΩΣΗΣ- ΑΠΟΚΩΔΙΚΟΠΟΙΗΣΗΣ ΤΗΣ BRAILLE ΑΠΟ ΑΤΟΜΑ ΜΕ ΤΥΦΛΩΣΗ

Παρατηρήσεις επί των συστάσεων: Competent Authority response received on 2 June 2008

Απόκριση σε Μοναδιαία Ωστική Δύναμη (Unit Impulse) Απόκριση σε Δυνάμεις Αυθαίρετα Μεταβαλλόμενες με το Χρόνο. Απόστολος Σ.

«Συντήρηση αχλαδιών σε νερό. υπό την παρουσία σπόρων σιναπιού (Sinapis arvensis).»

1) Abstract (To be organized as: background, aim, workpackages, expected results) (300 words max) Το όριο λέξεων θα είναι ελαστικό.

Β-αναστολείς στην ανεπίπλεκτη υπέρταση: Έχουν θέση? ΚΑΜΠΟΥΡΙΔΗΣ ΝΙΚΟΛΑΟΣ MD, MSc, PhD Διευθυντής ΕΣΥ Καρδιολογικής Κλινικής Γ.Ν.

TAMIL NADU PUBLIC SERVICE COMMISSION REVISED SCHEMES

CORDIC Background (2A)

ST5224: Advanced Statistical Theory II

Bulletin 1489 UL489 Circuit Breakers

Smaller. 6.3 to 100 After 1 minute's application of rated voltage at 20 C, leakage current is. not more than 0.03CV or 4 (µa), whichever is greater.

ΕΘΝΙΚΟ ΜΕΤΣΟΒΙΟ ΠΟΛΥΤΕΧΝΕΙΟ

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΤΜΗΜΑ ΝΟΣΗΛΕΥΤΙΚΗΣ

Aluminum Electrolytic Capacitors

Αζεκίλα Α. Μπνπράγηεξ (Α.Μ. 261)

AΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ ΠΟΛΥΤΕΧΝΙΚΗ ΣΧΟΛΗ ΤΜΗΜΑ ΠΟΛΙΤΙΚΩΝ ΜΗΧΑΝΙΚΩΝ

Ψηφιακή ανάπτυξη. Course Unit #1 : Κατανοώντας τις βασικές σύγχρονες ψηφιακές αρχές Thematic Unit #1 : Τεχνολογίες Web και CMS

ΠΑΡΑΡΤΗΜΑ ΔΙΕΘΝΕΣ ΠΙΣΤΟΠΟΙΗΤΙΚΟ ΔΙΑΧΕΙΡΙΣΗΣ ΕΡΜΑΤΟΣ INTERNATIONAL BALLAST WATER MANAGEMENT CERTIFICATE

Dynamic types, Lambda calculus machines Section and Practice Problems Apr 21 22, 2016

Transcript:

N. 22(III)/2014 ΕΠΙΗΜΗ ΕΦΗΜΕΡΙΔΑ ΣΗ ΚΤΠΡΙΑΚΗ ΔΗΜΟΚΡΑΣΙΑ ΠΑΡΑΡΣΗΜΑ ΠΡΩΣΟ ΝΟΜΟΘΕΙΑ - ΜΕΡΟ ΙII Αριθμός 4201 Σρίτη, 23 Δεκεμβρίοσ 2014 10803 Ο περί ηης Διεθνούς Σύμβαζης (ΟΥΝΕΣΚΟ) καηά ηοσ Νηόπινγκ ζηον Αθληηιζμό (Τροποποιηηικός) (Κσρωηικός) (Αρ. 2) Νόμος ηοσ 2014, εκδίδεηαι με δημοζίεσζη ζηην Επίζημη Εθημερίδα ηης Κσπριακής Δημοκραηίας ζύμθωνα με ηο Άρθρο 52 ηοσ Σσνηάγμαηος. Αξηζκόο 22(IIΙ) ηνπ 2014 ΝΟΜΟ ΠΟΤ ΣΡΟΠΟΠΟΙΔΙ ΣΟΤ ΠΔΡΙ ΣΗ ΓΙΔΘΝΟΤ ΤΜΒΑΗ (ΟΤΝΔΚΟ) ΚΑΣΑ ΣΟΤ ΝΣΟΠΙΝΓΚ ΣΟΝ ΑΘΛΗΣΙΜΟ (ΚΤΡΩΣΙΚΟΤ) ΝΟΜΟΤ ΣΟΤ 2009 ΔΩ 2014 Η Βνπιή ησλ Αληηπξνζώπσλ ςεθίδεη σο αθνινύζσο: πλνπηηθόο ηίηινο. 7(ΙΙΙ) ηνπ 2009 16(ΙΙΙ) ηνπ 2011 27(ΙΙΙ) ηνπ 2012 9(ΙΙΙ) ηνπ 2013 1(ΙΙΙ) ηνπ 2014. Σξνπνπνίεζε ηνπ άξζξνπ 2 ηνπ βαζηθνύ λόκνπ. Σξνπνπνίεζε ηνπ Πξώηνπ Πίλαθα ηνπ βαζηθνύ λόκνπ. Παξάξηεκα. 1. Ο παξώλ Νόκνο ζα αλαθέξεηαη σο ν πεξί ηεο Γηεζλνύο ύκβαζεο (ΟΤΝΔΚΟ) θαηά ηνπ Νηόπηλγθ ζηνλ Αζιεηηζκό (Σξνπνπνηεηηθόο) (Κπξσηηθόο) (Αξ. 2) Νόκνο ηνπ 2014 θαη ζα δηαβάδεηαη καδί κε ηνπο πεξί ηεο Γηεζλνύο ύκβαζεο (ΟΤΝΔΚΟ) θαηά ηνπ Νηόπηλγθ ζηνλ Αζιεηηζκό (Κπξσηηθνύο) Νόκνπο ηνπ 2009 έσο 2014, (πνπ ζηε ζπλέρεηα ζα αλαθέξνληαη σο «ν βαζηθόο λόκνο») θαη ν βαζηθόο λόκνο θαη ν παξώλ Νόκνο ζα αλαθέξνληαη καδί σο νη πεξί ηεο Γηεζλνύο ύκβαζεο (ΟΤΝΔΚΟ) θαηά ηνπ Νηόπηλγθ ζηνλ Αζιεηηζκό (Σξνπνπνηεηηθνί) (Κπξσηηθνί) Νόκνη ηνπ 2009 έσο (Αξ. 2) ηνπ 2014. 2. Σν άξζξν 2 ηνπ βαζηθνύ λόκνπ ηξνπνπνηείηαη κε ηελ αληηθαηάζηαζε ηεο παξαγξάθνπ (α) ηνπ όξνπ «Πξνζαξηήκαηα», κε ηελ αθόινπζε λέα παξάγξαθν: «(α) Πξνζάξηεκα Ι: Παγθόζκηνο Κώδηθαο Αληη-Νηόπηλγθ ΚΑΣΑΛΟΓΟ ΑΠΑΓΟΡΔΤΜΔΝΩΝ ΟΤΙΩΝ ΚΑΙ ΜΔΘΟΓΩΝ ΓΙΑ ΣΟ 2014 ΓΙΔΘΝΔΙ ΠΡΟΓΙΑΓΡΑΦΔ». Έθδνζε 2.0 (αλαζεσξεκέλε έθδνζε ηνπ 2014)». 3. Ο Πξώηνο Πίλαθαο ηνπ βαζηθνύ λόκνπ ηξνπνπνηείηαη κε ηελ αληηθαηάζηαζε ηνπ Πξνζαξηήκαηνο Ι, ην νπνίν πεξηιακβάλεηαη ζην Μέξνο Ι θαη ζην Μέξνο ΙΙ απηνύ, κε ην αθόινπζν λέν Πξνζάξηεκα Ι, ην νπνίν πεξηιακβάλεηαη ζην Παξάξηεκα ηνπ παξόληνο Νόκνπ, σο αθνινύζσο:

10804 «Παξάξηεκα Μέξνο Ι (Πξνζάξηεκα Ι ζηελ αγγιηθή) Μέξνο ΙΙ (Πξνζάξηεκα Ι ζηελ ειιεληθή).».

10805 Μέρος Ι (Προσάρτημα Ι στην αγγλική) The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014

10806 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as Specified except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous * AAS, including: 1-androstenediol (5 -androst-1-ene-3,17 -diol ); 1-androstenedione (5 androst-1-ene-3,17-dione); bolandiol (estr-4-ene- -diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 -ol); The revised 2014 Prohibited List 17 May 2014

10807 dehydrochlormethyltestosterone (4-chloro-17 -hydroxy-17 -methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17 -methyl-5 -androst-2-en- 17 -ol); drostanolone; ethylestrenol (19-norpregna-4-en-17 -ol); fluoxymesterone; formebolone; furazabol (17 methyl[1,2,5]oxadiazolo[3',4':2,3]-5 -androstan- -ol); gestrinone; 4- hydroxytestosterone (4,17 -dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metandienone (17 -hydroxy-17 -methylandrosta-1,4-dien-3- one); metenolone; methandriol; methasterone ( -hydroxy-2,17 dimethyl-5 -androstan-3-one); methyldienolone (17 -hydroxy-17 methylestra-4,9-dien-3-one); methyl-1-testosterone (17 -hydroxy-17 -methyl- 5 -androst-1-en-3-one); methylnortestosterone (17 -hydroxy-17 -methylestr- 4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17 hydroxy-17 -methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19- norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ( -[(tetrahydropyran-2-yl)oxy]-1'h-pyrazolo[3,4:2,3]-5 androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17 hydroxy-5 -androst-1-en-3-one); tetrahydrogestrinone (17-hydroxy-18ahomo-19-nor-17 -pregna-4,9,11-trien-3-one); trenbolone ( -hydroxyestr- 4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous ** AAS when administered exogenously: androstenediol (androst-5-ene-3,17 -diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17 -hydroxy-5 -androstan-3-one); prasterone (dehydroepiandrosterone, DHEA, -hydroxyandrost-5-en-17-one); testosterone; and their metabolites and isomers, including but not limited to: 5 -androstane-3,17 -diol; 5 -androstane-3,17 -diol; 5 -androstane- 3,17 -diol; 5 -androstane-3,17 -diol; androst-4-ene-3,17 -diol; androst-4-ene-3,17 -diol; androst-4-ene-3,17 -diol; androst-5-ene- 3,17 -diol; androst-5-ene-3,17 -diol; androst-5-ene-3,17 -diol; 4-androstenediol (androst-4-ene-3,17 -diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; etiocholanolone; 3 -hydroxy-5 -androstan-17-one; 3 -hydroxy-5 androstan-17-one; 7 -hydroxy-dhea ; 7 -hydroxy-dhea ; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. The revised 2014 Prohibited List 17 May 2014

10808 For purposes of this section: refers to a substance which is not ordinarily produced by the body naturally. ordinarily produced by the body naturally. S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (depo), hypoxia-inducible factor (HIF) stabilizers and activators (e.g. xenon, argon), methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)]; 2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, in males; 3. Corticotrophins and their releasing factors; 4. Growth Hormone (GH) and its releasing factors and Insulin-like Growth Factor-1 (IGF-1). In addition, the following growth factors are prohibited Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; and other substances with similar chemical structure or similar biological effect(s). S3. BETA-2 AGONISTS All beta-2 agonists, including all optical isomers (e.g. d- and l-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the regimen. The revised 2014 Prohibited List 17 May 2014

10809 The presence in urine of salbutamol in excess of 1000 ng/ml or formoterol in excess of 40 ng/ml is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above. S4. HORMONE AND METABOLIC MODULATORS The following are prohibited: 1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: a) Insulins b) Peroxisome -AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s). Local administration of felypressin in dental anaesthesia is not prohibited. Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, vaptans (e.g. tolvaptan); and other substances with a similar The revised 2014 Prohibited List 17 May 2014

10810 chemical structure or similar biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited). The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent. The revised 2014 Prohibited List 17 May 2014

10811 PROHIBITED METHODS M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M2. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control. These include but are not limited to urine substitution and/or adulteration (e.g. proteases). 2. Intravenous infusions and/or injections of more than 50 ml per 6 hour period except for those legitimately received in the course of hospital admissions or clinical investigations. M3. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues; 2. The use of normal or genetically modified cells. The revised 2014 Prohibited List 17 May 2014

10812 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants, including all optical isomers (e.g. d- and l-) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2014 Monitoring Program *. Stimulants include: a: Non-Specified Stimulants: Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine(d-); p-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants (examples): Benzfetamine; cathine ** ; cathinone and its analogues (e.g. mephedrone, methedrone, - pyrrolidinovalerophenone); dimethylamphetamine; ephedrine *** ; epinephrine **** (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroxyamphetamine); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxymethamphetamine; methylephedrine *** ; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine ***** ; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine); trimetazidine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). The revised 2014 Prohibited List 17 May 2014

10813 * The following substances included in the 2014 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, synephrine) are not considered as Prohibited Substances. ** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. **** Local administration (e.g. nasal, ophthalmologic) of epinephrine (adrenaline) or co-administration with local anaesthetic agents is not prohibited. ***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS The following are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9- tetrahydrocannabinol (THC) and cannabimimetics (e.g. JWH073, HU-210) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. The revised 2014 Prohibited List 17 May 2014

10814 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/l. Air Sports (FAI) Archery (WA) Automobile (FIA) Karate (WKF) Motorcycling (FIM) Powerboating (UIM) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. Archery (WA) (also prohibited Out-of-Competition) Automobile (FIA) Billiards (all disciplines) (WCBS) Darts (WDF) Golf (IGF) Shooting (ISSF, IPC) (also prohibited Out-of-Competition) Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The revised 2014 Prohibited List 17 May 2014

10815 Μέρος ΙΙ (Προσάρτημα Ι στην ελληνική) - 2014-2014

10816 14-1 2014-2 ( ) 0. (S0. NON-APPROVED SUBSTANCES) [, designer drugs), ] 1. (S1. ANABOLIC AGENTS). 1. ( ) (Anabolic Androgenic Steroids (AAS)). *, : (19- - -4- - ethylestrenol (19-norpregn-4-4 1 2014

10817-1- (5 - -1- - 3,17 - ) 1- - -1- - 3,17- ([1,2] - 4- -20- -17 - ) o (4- -17 - -17 - - 1,4- -3- ) (17 - -5 - -2- -17 - ) (17 - -17 - -1,4- -3- ) ( - - - - - -3- - - - -4,9- -3- o- - - -4- -3- o-1- - - - - - -1- -3- o ( o - - --4,9,11- -3- ( -4- - - ) -1,4- -3,17-19- -4- - 3,17- en-17 -ol) 1-androstenediol (5 -androst-1-ene- 3,17 -diol) 1-androstenedione (5 -androst-1- ene-3,17-dione) gestrinone danazol ([1,2]oxazolo[4',5':2,3] pregna-4-en-20-yn-17 -ol) dehydrochlormethyltestosterone (4-chloro-17 - hydroxy-17 methylandrosta-1,4-dien-3-one) desoxymethyltestosterone (17 methyl-5 -androst-2-ene-17 -ol) drostanolone calusterone quinbolone clostebol metenolone metandienone (17 -hydroxy-17 methylandrosta-1,4-dien-3-one) methandriol methasterone -hydroxy- dimethyl- -androstan-3-one) methyldienolone -hydroxy-17amethylestra-4,9-dien-3-one) methylnortestosterone (17 hydroxy-17 -methylestr-4-en-3-one) methyl-1-testosterone ( -hydroxy- 17 -methyl-5 -androst-1-en-3-one) methyltestosterone mestanolone mesterolone mibolerone metribolone (methyltrienolone, 17 - hydroxy-17 -methylestr-4,9,11-trien- 3-one) bolandiol (estr-4-ene- -diol) bolasterone boldenone boldione (androsta-1,4-diene-3,17- dione) nandrolone 19-norandrostenedione (estr-4-ene- 3,17-dione) norclostebol norboletone norethandrolone oxabolone oxandrolone 4 1 2014

10818-2- - - - - (17- - - -19- - - -4,9,11- -3-1- - - - -1- -3- - -4,9,11- -3-4- - -4- - ( - - - - - - - ) oxymetholone oxymesterone prostanozol ( tetrahydropyran-2- yl)oxy]-1'h-pyrazolo[3,4:2,3]-5 androstane) stanozolol stenbolone tetrahydrogestrinone (17-hydroxy- 18a-homo-19-nor-17 -pregna- 4,9,11-trien-3-one) 1-testosterone (17 -hydroxy-5 androst-1-en-3-one) trenbolone -hydroxyestr-4,9,11- trien-3-one) 4-hydroxytestosterone (4,17 dihydroxyandrost-4-en-3-one) fluoxymesterone formebolone furazabol (17 -methyl- -5 androstan-17 -ol) **. -5- - - -4- -3,17- (, (DHEA - -5- -17- : - - - - - - - - - - - - -4- - - -4- - - -4- - - -5- - - -5- - - androstenediol (androst-5-ene- 3,17 -diol) androstenedione (androst-4-ene- 3,17-dione) dihydrotestosterone prasterone (dehydroepiandrosterone, DHEA, 3 -hydroxyandrost-5-en-17- one) testosterone 5 -androstane-3,17 -diol 5 -androstane-3,17 -diol 5 -androstane-3,17 -diol 5 -androstane-3,17 -diol androst-4-ene-3,17 -diol androst-4-ene-3,17 -diol androst-4-ene-3,17 -diol androst-5-ene-3,17 -diol androst-5-ene-3,17 -diol 4 1 2014

10819-5- - - androst-5-ene-3,17 -diol 4- -4- - - 4-androstenediol (androst-4-ene- 3,17 -diol) 5- -5- -3,17-5-androstenedione (androst-5-ene- 3,17-dione) epi-dihydrotestosterone epitestosterone etiocholanolone 3 - -5 - -17-3 -hydroxy-5 -androstan-17-one 3 - -5 - -17-3 -hydroxy-5 -androstan-17-one 7 - - 7 -hydroxy-dhea - - 7 -hydroxy-dhea 7- - 7-keto-DHEA 19-19-norandrosterone 19-19-noretiocholanolone (2. Other Anabolic Agents) selective androgen receptor modulators (SARMs) zeranol zilpaterol clenbuterol tibolone : (S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES) 1. E Erythropoiesis- Stimulating Agents) [ Erythropoietin - EPO Darbepoietin - depo),, (hypoxia-inducible factor (HIF) stabilizers and activators (e.g. 4 5/16 1 2014

10820 xenon, argon), - - - (methoxy polyethylene glycol-epoetin beta - CERA), (peginesatide) - Hematide). 2. Chorionic Gonadotrophin - CG Luteinizing Hormone - LH) 3. Corticotrophins) 4. Growth Hormone - GH) - nsulinlike Growth Factor-1 - IGF-1) - Mechano Growth Factors - MGFs), Platelet- Derived Growth Factor - PGDF Fibroblast Growth Factors - FGFs - Vascular-Endothelial Growth Factor - VEGF (Hepatocyte Growth Factor - HGF), 3. 2- (S3. BETA-2 AGONISTS) - d- l-, salbutamol, formoterol ( 54 ) salmeterol. ng/ml) 40 ng/ml A, 4 1 2014

10821 (S4. HORMONE AND METABOLIC MODULATORS) : 1. aromatase inhibitors) -1,4,6- -3,17-4- -3,6,17- - anastrozole androsta-1,4,6-triene-3,17-dione (androstatrienedione) 4-androstene-3,6,17-trione (6- oxo) aminoglutethimide exemestane letrozole testolactone formestane 2. Selective Estrogen Receptor Modulators - SERMs) raloxifene tamoxifen toremifene 3. - clomiphene cyclofenil fulvestrant 4. myostatin inhibitors). 5. (insulins) [Peroxisome Proliferator Activated 4 1 2014

10822 Receptor (PPAR ) agonists], (.. GW 1516), PPAR -AMP- [PPAR -AMP-activated protein kinase (AMPK) axis agonists] (.. AICAR). (S5. DIURETICS AND OTHER MASKING AGENTS) plasma expanders (e.g. glycerol, intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol) desmopressin diuretics probenecid etacrynic acid acetazolamide amiloride vaptans (e.g. talvoptan) thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide) indapamide canrenone metolazone spironolactone triamterene furosemide chlortalidone drospirenone, 4 1 2014

10823 - pamabrom - dorzolamide brinzolamide formoterol, - salbutamol - cathine - ephedrine - methylephedrine - pseudoephedrine,. 4 1 2014

10824 M1. (M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS) : 1. ),. 2. - - perfluorochemicals - efaproxiral (RSR 3. M2. (M2. CHEMICAL AND PHYSICAL MANIPULATION) : 1.,, 2. ml M3. (M3. GENE DOPING) 1.. 2. H. 4 1 2014

10825 (S6. STIMULANTS) A, ( d- l-) 4*. E A d-) p- adrafinil amfepramone amiphenazole amfetamine amfetaminil benzylpiperazine benfluorex bromantan cocaine cropropamide crotetamide metamfetamine (d-) p-methylamphetamine mesocarb mefenorex mephentermine modafinil norfenfluramine prolintane prenylamine phendimetrazine fenetylline fencamine phenmetrazine fenproporex 4 1 2014

4 1 2014 phentermine fenfluramine [4- ( )] fonturacetam [4-phenylpiracetam (carphedon)] furfenorex clobenzorex E ( : etamivan etilamphetamine etilefrine benzphetamine dimethylamphetamine (****) epinephrine (adrenaline****) heptaminol ** ephedrine*** isometheptene ** cathine** -PVP) (e.g. mephedrone, methedrone, a- pyrrolidinovalerophenone) levmethamphetamine methylenedioxyamphetamine methylenedioxymethamphetamine ( ) methylhexaneamine (dimethylpentylamine) * methylephedrine*** methylsynephrine methylphenidate meclofenoxate nikethamide norfenefrine octopamine ( ) oxilofrine (methylsynephrine) pemoline pentetrazole propylhexedrine selegiline 10826

10827 ( sibutramine strychnine tenamfetamine (methylenedioxyamphetamine) tuaminoheptane trimetazidine hydroxyamfetamine (parahydroxyamfetamine) fenbutrazate fencamfamin phenpromethamine famprofazone pseudoephedrine***** A O - 2014 - bupropion - caffeine, nicotine, - phenylephrine - - phenylpropanolamine, - pipradol - synephrine). ** -cathine - ephedrine - methylephedrine **** ( ) epinephrine (adrenaline). - pseudoephedrine (S7. NARCOTICS) - buprenorphine dextromoramide diamorphine (heroin) 4 1 2014

10828 methadone morphine oxycodone oxymorphone pentazocine pethidine hydromorphone fentanyl and its derivatives (S8. CANNABINOIDS) - -tetrahydrocannabinol THC ( Spice, JWH018, JWH073, HU-210). (S9. GLUCOCORTICOSTEROIDS) 4 1 2014

10829 (P1. ALCOHOL) To 0,10 g/l). - FAI) - WA, o - FIA) - WKF) - FIM) Powerboating Powerboating - UIM) (P2. BETA BLOCKERS) - WA) - FIA) - WCBS) WDF) - IGF) ISSF - IPC A - FIS) acebutolol alprenolol atenolol betaxolol bisoprolol 4 1 2014

10830 bunolol esmolol carteolol carvedilol celiprolol labetalol levobunolol metipranolol metoprolol nadolol oxprenolol pindolol propranolol sotalol timolol